ClinicalTrials.gg
Not yet recruitingNCT07628933Updated Jun 5, 2026

A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke

A Phase 1 interventional study of Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection and Human Umbilical Cord Mesenchymal Stem Cells Injection in Acute Ischemic Stroke and AIS, sponsored by BOE Technology Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by BOE Technology Group Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
517th of 563
35 · median 266
Started
2026
with 121 others
Phase 1
28 of 750
10 open now
Primary completion
2028-03
later than 299 of 395 live
Registered
697th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 517th largest by planned enrollment of the 563 interventional ones that give a count, is one of 122 that started in 2026, is one of 28 in phase 1, reaches primary completion later than 299 of the 395 other live ones, and was the 697th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Study Methods: The trial consists of two phases, both including a placebo control.

Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set. This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Dose escalation to the next level is permitted only after safety assessment at 28 days post-dose in the previous group.

Phase Ib (multiple-dose): Based on Phase Ia results, two dose groups will be selected. The product is administered on Day 0, Day 7, and Day 14 (3 doses total). The trial remains randomized, double-blind, and placebo-controlled.

Read the detailed description

Objective of this study: To preliminarily evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stromal cell injection in the treatment of AIS.

Study methods: This trial is divided into two phases, both including a placebo control.

Phase I (Ia): A multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Three dose groups are set: low dose (5.0×10⁷ cells), medium dose (1.0×10⁸ cells), and high dose (2.0×10⁸ cells). The low-dose group enrolls 3-6 participants (all receiving the investigational product, with the first of the first 3 participants as a sentinel). The medium- and high-dose groups each enroll 8 participants (2 sentinels receiving the investigational product, and the remaining 6 randomized in a 2:1 ratio to the investigational product or placebo group). Phase Ia plans to enroll 19-22 participants. Dose escalation to the next dose group is permitted only after all participants in the previous dose group have completed dosing and been observed for at least 28 days with a favorable safety assessment.

Phase Ib: A multicenter, randomized, double-blind, placebo-controlled, dose-escalation, multiple-dose trial. Based on the results of Phase Ia, two dose groups will be selected. The initial plan is to administer the product on Day 0, Day 7, and Day 14 (3 doses in total). Each dose group enrolls 8 participants (6 receiving the investigational product, 2 receiving placebo), for a total of 16 participants. Escalation to the next higher dose group is permitted only after all participants in the previous dose group have completed the three doses and been observed for at least 28 days with a favorable safety assessment.

Study duration: 720 days

03

Conditions studied

  • Acute Ischemic Stroke
  • AIS

Browse trials for

Keywords

  • AIS
  • hUC-MSCs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years, both genders included.
  • Clinical diagnosis of anterior circulation ischemic stroke, and able to receive the product within 48 hours after the onset of stroke symptoms.
  • National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive), with a score of \<2 on item Ia of the NIHSS.
  • Pre-stroke modified Rankin Scale (mRS) score ≤1.
  • The participant voluntarily agrees to participate in this study, signs the form personally or via a legal guardian, and has good compliance.

Exclusion criteria

Exclusion Criteria:

  • Planned or already performed thrombectomy for the current stroke.
  • Treatment with neuroprotective agents after the current stroke.
  • History of cerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after the current ischemic stroke, and judged by the investigator to be unsuitable for participation in the clinical trial.
  • Uncontrolled systemic diseases, including but not limited to: hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure ≥100 mmHg), diabetes mellitus (acute diabetic complications such as ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, or hypoglycemic coma within the past 3 months, or >8.5%, or poorly controlled blood glucose [blood glucose >16.8 mmol/L or \<2.8 mmol/L]), renal disease ( \<30 mL/min), liver failure ( Class C), severe heart failure ( [NYHA] Class IV), severe chronic respiratory disease.
  • Organ function meeting any one or more of the following criteria:

    1. (ANC) \<1.5×10⁹/L, count (PLT) \<100×10⁹/L, (Hb) \<90 g/L;
    2. (AST) >2.5× (ULN) and/or alanine aminotransferase (ALT) >2.5×ULN, serum total (TBIL) >1.5×ULN;
    3. Creatinine (Cr) >1.5×ULN;
    4. For patients not receiving anticoagulant or antithrombotic therapy: (INR) >1.7 or activated partial thromboplastin time (APTT) >1.25×ULN; for patients receiving anticoagulant or antithrombotic therapy: INR >3.0 or APTT >1.5×ULN.
  • Diagnosis of immunodeficiency disease, or long-term use of or systemic at high doses within a short period before screening.
  • Epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological or psychiatric disorders that, in the investigator's opinion, could affect the participant's ability to participate in the trial or interfere with study assessments.
  • Presence of diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.).
  • Inability to undergo cranial CT/MRI examination for any reason (e.g., metallic implants such as cardiac pacemakers, claustrophobia, etc.).
  • Participation in another clinical trial of an drug within 3 months before screening.
  • Pregnancy, breastfeeding, planned pregnancy, or inability to use effective measures.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Human Umbilical Cord Mesenchymal Stromal Cells Injection(low-dose group)

    5.0×10\^7 cells,Single intravenous infusion

    Drug: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stromal Cells Injection(medium-dose group)

    1.0×10\^8 cells,Single intravenous infusion

    Drug: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stromal Cells Injection(high-dose group)

    2.0×10\^8 cells,Single intravenous infusion

    Drug: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Placebo comparator
    Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection(medium-dose group)

    1.0×10\^8 cells,Single intravenous infusion

    Drug: Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection

  • Placebo comparator
    Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection(high-dose group)

    2.0×10\^8 cells,Single intravenous infusion

    Drug: Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stromal Cells Injection 1

    Based on the results from the Phase Ia trial, dose group 1 will be considered for the Phase Ib trial.For multiple dosing, it is initially planned to administer the injection once on Day 0, Day 7, and Day 14, for a total of 3 doses.

    Drug: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stromal Cells Injection 2

    Based on the results from the Phase Ia trial, dose group 2 will be considered for the Phase Ib trial.For multiple dosing, it is initially planned to administer the injection once on Day 0, Day 7, and Day 14, for a total of 3 doses.

    Drug: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Placebo comparator
    Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection 1

    Based on the results from the Phase Ia trial, dose group 1 will be considered for the Phase Ib trial.For multiple dosing, it is initially planned to administer the injection once on Day 0, Day 7, and Day 14, for a total of 3 doses.

    Drug: Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection

  • Placebo comparator
    Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection 2

    Based on the results from the Phase Ia trial, dose group 2 will be considered for the Phase Ib trial.For multiple dosing, it is initially planned to administer the injection once on Day 0, Day 7, and Day 14, for a total of 3 doses.

    Drug: Placebo of Human Umbilical Cord Mesenchymal Stromal Cells Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of DLT (Dose-Limiting Toxicity) events;

    Time frame: Day28

  2. All adverse events/serious adverse events during the trial;

    Time frame: 2year

  3. All-cause mortality

    Time frame: Day90、Day180、Day360

Secondary outcomes

  1. Proportion of participants with an Modified Rankin Scale (mRS) score of 0-2

    The modified Rankin Scale (mRS) is a widely used clinical outcome measure that assesses the degree of disability or dependence in the daily activities of patients who have suffered a stroke or other neurological conditions. It is a simple, 7-level ordinal scale ranging from 0 to 6: 0 - No symptoms at all. 1. \- No significant disability: able to perform all usual activities despite some symptoms. 2. \- Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance. 3. \- Moderate disability: requires some help but able to walk without assistance. 4. \- Moderately severe disability: unable to walk or attend to bodily needs without assistance. 5. \- Severe disability: bedridden, incontinent, requiring constant nursing care. 6. \- Dead. A higher score indicates more severe disability. The mRS is the most common primary endpoint in acute stroke clinical trials, with a score of 0-2 at 90 days often defined as a "good outcome.

    Time frame: Day 30, Day90, Day180, Day360

  2. Proportion of participants with a ≥4-point improvement in National Institutes of Health Stroke Scale (NIHSS) score from baseline

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized tool used to objectively quantify the severity of neurological deficits in patients with stroke. It consists of 15 items, including assessments of consciousness, eye movements, visual fields, facial palsy, motor and sensory function, language, speech, and neglect. Each item is scored, with a total score ranging from 0 to 42. Higher scores indicate more severe neurological impairment. The NIHSS is widely used in clinical practice and research to evaluate stroke severity, guide treatment decisions, and predict patient outcomes.

    Time frame: Day 7, Day 14, Day 30, Day 90, Day 180, Day 360

  3. Change from baseline in National Institutes of Health Stroke Scale(NIHSS) score

    Time frame: Day 7, Day 14, Day 30, Day 90, Day 180, Day 360

  4. Proportion of participants with a Barthel Index ≥95

    The Barthel Index (BI) is a standardized ordinal scale used to measure a person's performance in activities of daily living (ADL). It assesses 10 basic functions, including feeding, bathing, grooming, dressing, bowel and bladder control, toilet use, transfers (e.g., bed to chair), mobility, and stair climbing. Each item is scored based on the amount of physical assistance required, with total scores typically ranging from 0 to 100 (or 0-20 in some versions). It is widely used in geriatrics, rehabilitation, and stroke research to evaluate functional independence and track changes over time.A higher Barthel Index score indicates greater functional independence (less need for assistance), while a lower score reflects greater disability and dependency. For example, a score of 100 means the patient is fully independent in basic ADL.

    Time frame: Day 30, Day 90, Day180, Day360

  5. Change from baseline in the Fugl-Meyer Motor Function Assessment Scale score

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index widely recognized as a gold standard scale for evaluating sensorimotor recovery in patients with post-stroke hemiplegia. A higher FMA score indicates better motor function and less impairment, reflecting more positive outcomes in stroke recovery. For example, the motor domain score ranges from 0 (complete hemiplegia) to 100 (normal motor performance). The total FMA score is therefore a direct measure of functional recovery: the higher the score, the greater the improvement in sensorimotor function following stroke.

    Time frame: Day 30, Day90, Day180, Day 360

  6. Change from baseline in objective imaging findings (CT/MRI)

    Time frame: Day 90

Other outcomes

  1. mmunogenicity: Human Leukocyte Antigen (HLA) antibodies.

    Time frame: Within 60 minutes before the first dose, and at 14 days, 30 days, and 90 days after the start of the first dose administration.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Mar 2028, 21 months later.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 5, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Nov 30, 2029
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07628933
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Jun 5, 2026

Study contacts

Yongjun Wang Chief Physician, Professor
Contact
yongjunwang111@aliyun.com
010-59978538

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion